Friday, June 26, 2015 10:22:34 PM
What's a good way to compare different stocks? One of the best methods of comparison is to look at stocks' returns on equity, or ROE. This financial metric shows the amount of net income as a percentage of shareholders' equity. Shareholders' equity, also known as book value, is calculated by subtracting total liabilities of a company from its total assets.
It's best to use ROE for comparing stocks within the same sector. Different dynamics drive different sectors. But looking at ROE values for stocks in the same sector can help investors more effectively stocks to put on their watchlists. If you're wanting to buy healthcare stocks, for example, examining ROE is a good place to start. These three stocks have the best returns on equity across all of healthcare.
1. Catalent (NYSE:CTLT)
The highest ROE among healthcare stocks with a market cap of at least $250 million belongs to a company you might not have heard of. Catalent's ROE currently stands just under 218% -- twice as high as the second-place healthcare company.
While Catalent's initial public offering was less than a year ago, the company isn't new to the scene. Cardinal Health spent years scooping up oral drug delivery technologies before ultimately spinning off the business in 2007, which ultimately became known as Catalent.
Catalent focuses on three different areas -- oral technologies, medication delivery solutions, and development and clinical services. Oral technologies generate over 60% of total revenue and nearly 90% of total earnings. What's really impressive about this business model is that nearly half of new chemical entities approved by the FDA over the last decade relied on Catalent's technology in some way!
Catalent's ROE is impressive, but some of its other financial metrics aren't. For example, revenue dropped slightly last quarter compared to the same quarter in 2014. Catalent's profit margin is less than 5%. And the company carries $1.88 billion in debt on its balance sheet with a little over $116 million in cash (including cash equivalents).
2. GlaxoSmithKline plc (NYSE:GSK)
Big pharmaceutical company GlaxoSmithKline claims the No. 2 spot on our list with a return on equity of nearly 108%. Glaxo's products include household names like Aquafresh toothpaste and Nicoderm patches and prescription medications from Advair to Zantac.
Glaxo looks attractive on other financial measures also. The stock's trailing price-to-earnings multiple is a low 6.58. Glaxo's profit margin of over 44% isn't bad at all. And Glaxo's dividend yields 5.3% with a low payout ratio of only 41%.
Before you rush to buy this stock, though, you might want to consider some challenges facing GlaxoSmithKline. Blockbuster respiratory drug Advair is experiencing declining sales and could be in for more difficulties when the patent for the Diskus inhaler expires next year. Glaxo also recently made a big bet by selling its oncology business and acquiring the vaccine business of Novartis. There are a lot of things in flux for this drugmaker that could drag that lofty ROE value downward in the near future.
3. Medivation (NASDAQ:MDVN)
Medivation's return on equity of just under 104% ranks it as the top biotech stock and third-highest healthcare stock. The company's success comes from prostate cancer drug Xtandi, which generated over $129 million in revenue for Medivation in the first quarter this year. Xtandi racked up over $1 billion in sales in 2014. Medivation splits this revenue with collaboration partner Astellas Pharma.
Outside of ROE, Medivation's financial metrics are something of a mixed bag. The biotech saw strong revenue growth last quarter, but earnings dropped from the same quarter in the prior year. Medivation's balance sheet looks pretty solid, with debt of a little over $245 million and cash of almost $569 million. However, the stock appears to be pricey with a trailing P/E of 32 and forward multiple just below 30.
Medivation's future success, like its current success, rides on Xtandi. Several clinical studies are currently under way for the drug in other stages of prostate cancer. Xtandi also is being studied as a potential treatment for breast cancer. Good news on those fronts should keep Medivation rolling.
Looking ahead
If we only used ROE as our criterion for selecting a healthcare stock, Catalent would win hands down. However, basing an investing decision on just one factor is never a smart idea.
My view is that Catalent should continue to do well. It has a solid business model and a diverse customer base. On the other hand, don't expect sizzling earnings growth for Catalent.
I'm taking a wait-and-see stance with Glaxo. Maybe the Novartis deal will turn out to be a good one. With generic competition for Advair on the way, though, I'm leery of this Big Pharma stock despite its compelling ROE.
Out of the three, I'm most bullish about Medivation. Xtandi should continue to perform well. And I wouldn't be surprised to see a bigger player ultimately buy Medivation.
Recent GSK News
- Alector Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024) • GlobeNewswire Inc. • 09/19/2024 12:00:00 PM
- AIG names new CFO; Progyny Drops 24% After Losing Key 2025 Contract; Exicure Jumps 190% With Nasdaq Extension • IH Market News • 09/19/2024 10:26:48 AM
- GSK Announces Positive Topline Data on Co-Administration of AREXVY and SHINGRIX • Business Wire • 09/18/2024 11:00:00 AM
- Brooke Shields Partners with GSK to Educate Adults 50 and Older About Their Shingles Risk • PR Newswire (US) • 09/16/2024 05:04:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/13/2024 10:29:21 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/12/2024 02:56:42 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/12/2024 10:34:23 AM
- GameStop plunges 11% on stock offering, DJT drops post-debate, GSK fails shingles vaccine trial • IH Market News • 09/11/2024 10:25:41 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/06/2024 03:12:06 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/06/2024 10:14:20 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/03/2024 10:17:38 AM
- High Volatility Expected in Nvidia Report, Ambarella Soars 20%, Hertz Strengthens Board, Apple Cuts Jobs • IH Market News • 08/28/2024 09:50:36 AM
- Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12% • GlobeNewswire Inc. • 08/06/2024 08:05:00 PM
- US FDA expands Jemperli (dostarlimab-gxly) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology-based treatment to show an overall survival benefit • Business Wire • 08/01/2024 07:44:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/31/2024 04:28:02 PM
- F5 Shares Rise 15%; Diageo Falls 10% on Annual Sales Decline; BP Boosts Dividend and Buyback Program • IH Market News • 07/30/2024 10:03:59 AM
- Apple Delays AI Features, Abbott Shares Plunge 7% After $495M Fine, Philips Soars 10% • IH Market News • 07/29/2024 10:24:10 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/29/2024 10:23:53 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/29/2024 10:16:02 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/19/2024 11:08:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/18/2024 03:53:17 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/16/2024 02:44:28 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/15/2024 05:14:52 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/12/2024 03:15:35 PM
- GSK Begins Shipping Influenza Vaccine Doses for 2024-25 Season • Business Wire • 07/11/2024 12:00:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM